Abstract
Purpose
Bevacizumab-related imaging abnormality (BRIA), appearing as areas of restricted diffusion on magnetic resonance imaging (MRI) and representing atypical coagulative necrosis pathologically, has been observed in patients with brain tumors receiving radiotherapy and bevacizumab. We investigated the role of cumulative radiation dose in BRIA development in a voxel-wise analysis.
Methods
Patients (n = 18) with BRIA were identified. All had high-grade gliomas or brain metastases treated with radiotherapy and bevacizumab. Areas of BRIA were segmented semi-automatically on diffusion-weighted MRI with apparent diffusion coefficient (ADC) images. To avoid confounding by possible tumor, hypoperfusion was confirmed with perfusion imaging. ADC images and radiation dose maps were co-registered to a high-resolution T1-weighted MRI and registration accuracy was verified. Voxel-wise normal tissue complication probability analyses were performed using a logistic model analyzing the relationship between cumulative voxel equivalent total dose in 2 Gy fractions (EQD2) and BRIA development at each voxel. Confidence intervals for regression model predictions were estimated with bootstrapping.
Results
Among 18 patients, 39 brain tumors were treated. Patients received a median of 4.5 cycles of bevacizumab and 1–4 radiation courses prior to BRIA appearance. Most (64%) treated tumors overlapped with areas of BRIA. The median proportion of each BRIA region of interest volume overlapping with tumor was 98%. We found a dose-dependent association between cumulative voxel EQD2 and the relative probability of BRIA (β0 = -5.1, β1 = 0.03 Gy-1, γ = 1.3).
Conclusions
BRIA is likely a radiation dose-dependent phenomenon in patients with brain tumors receiving bevacizumab and radiotherapy. The combination of radiation effects and tumor microenvironmental factors in potentiating BRIA in this population should be further investigated.
Funder
Foundation for the National Institutes of Health
American Cancer Society
Publisher
Public Library of Science (PLoS)
Reference35 articles.
1. Burt Nabors L, Ahluwalia M, Baehring J, Brem H, Butowski N, Helen Diller Family U, et al. NCCN Guidelines Version 1.2019: Anaplastic Gliomas/Glioblastoma [Internet]. 2019 [cited 2019 Aug 5]. https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf
2. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial;MJ van den Bent;Lancet Oncol,2018
3. Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases;AS Berghoff;Neuro-Oncology Adv,2020
4. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy;RK Jain;Science (80-),2005
5. Brandsma D, Van Den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Current Opinion in Neurology. 2009.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bevacizumab;Reactions Weekly;2023-04-08